About Us
Meet Nina Jaitly, MD, MPH, MS.
Physician-scientist. Public health strategist. Founder of AxonPeptide.
AxonPeptide was built around a simple belief: research materials deserve stronger documentation, clearer verification, and more scientific accountability than vague claims or generic certificates can provide.
Built for the gap between science and supply.
Dr. Nina Jaitly founded AxonPeptide after seeing how fragmented this category had become — positioned between academic research, pharmaceutical regulation, wellness demand, and online consumer experimentation.
Axon was built as a scientific stewardship company focused on sourcing, documentation review, independent verification, and public-facing transparency.
"This industry does not need louder marketing. It needs better documentation, better education, and better accountability."
A career across research, medicine, and drug development.
Dr. Jaitly's background spans NIH research systems, pharmaceutical drug development, academic medicine, neuroimmunology, and public health.
Scientific program leadership, research review, inflammation initiatives, biosafety coordination, and cross-disciplinary scientific collaboration.
Medical director overseeing neurology assets and lifecycle activities across multiple therapeutic and clinical trial programs.
Training in public health, biostatistics, epidemiology, risk communication, and population-level thinking informs Axon's transparency-first model.
NIH Scientific Review & Research Leadership
Dr. Jaitly's federal research career included scientific review work and program leadership across biomedical research, inflammation, biosafety, and emergency response initiatives.
Pharmaceutical Drug Development
At Novartis Pharmaceuticals, Dr. Jaitly served in medical leadership supporting neurology assets and lifecycle activities for therapies in multiple sclerosis, Parkinson's, Alzheimer's, and related neurological programs.
Clinical & Academic Training
Her clinical and academic background includes neuropsychiatry residency training, neuroimmunology fellowship training, immunology education, and peer-reviewed scientific publications.
AxonPeptide
At Axon, Dr. Jaitly leads scientific direction, product research, documentation strategy, and quality oversight within a research-use-only supply model.
Education, training, and professional foundation.
Academic Credentials
MD — Windsor University School of Medicine
MS, Biology & Molecular Immunology — University of Geneva
MPH, Applied Epidemiology & Biostatistics — University of Massachusetts Amherst
Clinical & Research Training
Residency Training — Neuropsychiatry, University of Massachusetts Medical School
Fellowship Training — Neuroimmunology
IRTA Fellowship — NIH Scientific Review Board
Published Research — Neurology, Neuropsychopharmacology, Psychoneuroendocrinology, Health Security, and related collaborations.
An independent laboratory network.
AxonPeptide operates a two-phase verification model built around three separate independent analytical laboratories — designed to reduce overreliance on any single testing source and create stronger documentation transparency across our supply chain.
Rather than relying on a single certificate of analysis from one laboratory, our verification process distributes analytical responsibility across multiple partners that each serve a distinct role. ARS Labs performs primary molecule-specific validation on every batch — and plays a pivotal role in supplier vetting and ongoing supplier quality assurance. A randomized subset of batches is then routed to Kovera Labs or Freedom Diagnostics for independent secondary verification.
Primary molecular validation partner. HPLC purity, LC-MS identity confirmation, endotoxin screening, and compound-specific analytical review prior to release. Also plays a pivotal role in supplier vetting and ongoing supplier quality assurance. Independently operated, with separation from AxonPeptide enforced by the Medical Stewardship Council.
Randomized secondary validation partner. Independent verification of a randomized subset of released batches to confirm consistency and reduce single-source bias.
Independent cross-verification partner. Additional analytical redundancy and long-term batch monitoring across the broader supply chain.
The independence of these laboratories is structural, not branded. ARS Labs is independently operated — separation between ARS Labs and AxonPeptide is enforced by the Medical Stewardship Council. Kovera Labs and Freedom Diagnostics are separate analytical operations engaged for randomized secondary verification. This distributed model is what makes the verification process meaningful: no batch is released on the strength of a single certificate from a single source.
Verification records produced through this network are housed on AxonVerified, where each batch can be reviewed individually alongside its supporting documentation.
Proof over promise. Documentation over hype.
AxonPeptide was created to raise the standard for how research materials are sourced, reviewed, verified, documented, and communicated.
- Lot-specific documentation
- Independent analytical review
- Supplier vetting and traceability
- Public-facing verification records
- RUO-focused education
- Physician-led scientific direction
No testing model can eliminate every uncertainty. Axon's goal is to provide stronger transparency, better documentation, and more reviewable data so researchers can make more informed decisions.
A more transparent research supply model.
Axon exists for researchers, educators, and professionals who want reviewable documentation — not empty certainty claims. Our mission is to make stronger verification, clearer records, and better scientific communication the baseline expectation in this category.
AxonPeptide does not provide medical advice, dosing guidance, treatment recommendations, or instructions for human or veterinary use. All materials are supplied strictly for qualified laboratory research, analytical, and educational purposes.